|

Esketamine hydrochloride Clinical Trials

3 actively recruiting trials

Also known as: N015X14

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Dr. Inge Winter2
  • Christian Hassager1

Indications

  • Major Depressive Disorder2
  • Depression2
  • Out-of-hospital Cardiac Arrest (OHCA)1
  • Schizophrenia and Related Disorders1
  • Treatment-resistant Depression1

Other3 trials

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Phase 3
Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
Phase 2
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.